Securities code: 002424 securities abbreviation: Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) Announcement No.: 2022-012 Guizhou Bailing Group Pharmaceutical Co.Ltd(002424)
2021 annual performance express
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special note: the financial data of 2021 contained in this announcement is only preliminary accounting data, which has been audited by the company’s internal audit department and has not been audited by an accounting firm. It may be different from the final data disclosed in the annual report. Investors are reminded to pay attention to investment risks.
1、 Main financial data and indicators in 2021
Unit: Yuan
Increase and decrease of the project in the same period of last year in the reporting period
Total operating income 3093235454.57 308788201.57 0.17%
Operating profit 181930464.95 196656099.67 – 7.49%
Total profit 148864197.23 208770014.02 – 28.69%
Net profit attributable to shareholders of listed companies 122600854.27 152375357.74 – 19.54%
Net profit attributable to shareholders of listed company 74862266.34 76068232.38 – 1.59% after deducting non recurring profit and loss
Basic earnings per share 0.09 0.11 – 18.18%
Weighted average return on net assets 3.14% – 0.70%
Increase / decrease range of the project at the end of the reporting period and at the beginning of the reporting period
Total assets 6482362615.84 7032834480.26 – 7.83%
Owner’s equity attributable to shareholders of listed companies 3916306662.25 3893859870.09 0.58%
Share capital 1411200000.00 1411200000.00 0
Net assets per share attributable to shareholders of listed companies 2.78 2.76 0.72%
Note: the above data are filled in with the data of the company’s consolidated statements.
2、 Description of operating performance and financial status
1. Operating performance
In 2021, the company achieved a total operating revenue of 3093235500 yuan, an increase of 0.17% over the same period of last year; The operating profit was 181930500 yuan, a decrease of 7.49% over the same period last year; The total profit was 148.8642 million yuan, a decrease of 28.69% over the same period last year; The net profit attributable to shareholders of listed companies was 122.6009 million yuan, down 19.54% from the same period of last year.
During the reporting period, the main reasons for the change of the company’s operating performance are as follows:
(1) In 2021, the scope of the company’s consolidated statements changed, and the former holding subsidiary Anshun dahealth Pharmaceutical Industry Operation Co., Ltd. (hereinafter referred to as “dahealth pharmaceutical”) was changed to a joint-stock subsidiary. Excluding the impact of dahealth pharmaceutical’s operating revenue in 2020, the company’s operating revenue in 2021 actually increased by 10.90%. (2) In 2021, under the influence of administrative fines imposed by the controlled subsidiary Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) enterprise group and Rentang Pharmaceutical Co., Ltd., the net non operating revenue and expenditure was -33.0663 million yuan, and the net non operating revenue and expenditure of the company in 2020 was 12.3319 million yuan. The above matters led to a year-on-year decrease in the net profit attributable to the shareholders of Listed Companies in 2021.
2. Financial situation
At the end of the reporting period, the company’s total asset balance was 6482362600 yuan, a decrease of 7.83% over the beginning of the period; The balance of owner’s equity attributable to shareholders of listed companies was 3916.3067 million yuan, an increase of 0.58% over the beginning of the period; The net asset per share was 2.78 yuan, an increase of 0.72% over the beginning of the period.
3、 Description of the difference from the previous performance forecast
Before the disclosure of this performance express, the company did not disclose the expected operating performance in 2021.
4、 Documents for future reference
1. Comparative balance sheet and income statement signed and sealed by the current legal representative of the company, the person in charge of accounting and the person in charge of accounting organization;
2. The internal audit report signed by the head of the internal audit department;
3. Other documents required by Shenzhen Stock Exchange.
It is hereby announced.
Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) board of directors
February 25, 2022
